These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

702 related articles for article (PubMed ID: 2994938)

  • 21. Evolution of angiotensin-converting enzyme inhibitors.
    Wyvratt MJ
    Clin Physiol Biochem; 1988; 6(3-4):217-29. PubMed ID: 2849521
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Enalapril clinical pharmacokinetics and pharmacokinetic-pharmacodynamic relationships. An overview.
    MacFadyen RJ; Meredith PA; Elliott HL
    Clin Pharmacokinet; 1993 Oct; 25(4):274-82. PubMed ID: 8261712
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Differences in first dose response to angiotensin converting enzyme inhibition in congestive heart failure: a placebo controlled study.
    MacFadyen RJ; Lees KR; Reid JL
    Br Heart J; 1991 Sep; 66(3):206-11. PubMed ID: 1657084
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Newer ACE inhibitors. A look at the future.
    Salvetti A
    Drugs; 1990 Dec; 40(6):800-28. PubMed ID: 2078997
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Differential effects of captopril and enalapril on tissue renin-angiotensin systems in experimental heart failure.
    Hirsch AT; Talsness CE; Smith AD; Schunkert H; Ingelfinger JR; Dzau VJ
    Circulation; 1992 Nov; 86(5):1566-74. PubMed ID: 1330361
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The clinical pharmacology of enalapril.
    Gomez HJ; Cirillo VJ; Jones KH
    J Hypertens Suppl; 1983 Oct; 1(1):65-70. PubMed ID: 6100610
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Enalaprilat, a new parenteral angiotensin-converting enzyme inhibitor: rapid changes in systemic and coronary hemodynamics and humoral profile in chronic heart failure.
    De Marco T; Daly PA; Liu M; Kayser S; Parmley WW; Chatterjee K
    J Am Coll Cardiol; 1987 May; 9(5):1131-8. PubMed ID: 3033043
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The design and properties of N-carboxyalkyldipeptide inhibitors of angiotensin-converting enzyme.
    Patchett AA; Cordes EH
    Adv Enzymol Relat Areas Mol Biol; 1985; 57():1-84. PubMed ID: 2994404
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Angiotensin-converting enzyme inhibitors: are they all alike?
    Case DB
    J Clin Hypertens; 1987 Sep; 3(3):243-56. PubMed ID: 2822859
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hormonal and metabolic effects of angiotensin converting enzyme inhibitors. Possible differences between enalapril and captopril.
    Atlas SA; Case DB; Yu ZY; Laragh JH
    Am J Med; 1984 Aug; 77(2A):13-7. PubMed ID: 6089554
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Overview: the role of angiotensin-converting enzyme inhibitors in cardiovascular therapy.
    Abrams WB; Davies RO; Ferguson RK
    Fed Proc; 1984 Apr; 43(5):1314-21. PubMed ID: 6323221
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of spirapril and captopril on regional blood flow in chronic congestive heart failure: a comparison between a short- and a long-acting angiotensin-converting enzyme inhibitor.
    van den Broek SA; de Graeff PA; Smit AJ; Girbes AR; Journée ; van Gilst WH; Hillege H; van Veldhuisen DJ; Wesseling H; Lie KI
    J Cardiovasc Pharmacol; 1995 Jan; 25(1):105-12. PubMed ID: 7723338
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Short- and long-acting angiotensin-converting enzyme inhibitors: a randomized trial of lisinopril versus captopril in the treatment of congestive heart failure. The Multicenter Lisinopril-Captopril Congestive Heart Failure Study Group.
    Giles TD; Katz R; Sullivan JM; Wolfson P; Haugland M; Kirlin P; Powers E; Rich S; Hackshaw B; Chiaramida A
    J Am Coll Cardiol; 1989 May; 13(6):1240-7. PubMed ID: 2539403
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Influence of diabetes mellitus on changes in left ventricular performance and renal function produced by converting enzyme inhibition in patients with severe chronic heart failure.
    Packer M; Lee WH; Medina N; Yushak M; Kessler PD; Gottlieb SS
    Am J Med; 1987 Jun; 82(6):1119-26. PubMed ID: 3037896
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetics and pharmacodynamics of enalapril in patients with congestive heart failure and patients with hypertension.
    Schwartz JB; Taylor A; Abernethy D; O'Meara M; Farmer J; Young J; Nelson E; Pool J; Mitchell JR
    J Cardiovasc Pharmacol; 1985; 7(4):767-76. PubMed ID: 2410720
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A three year clinical review of the impact of angiotensin converting enzyme inhibitors on the intra hospital mortality of congestive heart failure in Nigerians.
    Adewole AD; Ikem RT; Adigun AQ; Akintomide AO; Balogun MO; Ajayi AA
    Cent Afr J Med; 1996 Aug; 42(8):253-5. PubMed ID: 8990572
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical experience with converting-enzyme inhibitors in hypertension.
    Weber MA
    Am J Kidney Dis; 1987 Jul; 10(1 Suppl 1):45-51. PubMed ID: 3037889
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adverse reactions with angiotensin converting enzyme (ACE) inhibitors.
    DiBianco R
    Med Toxicol; 1986; 1(2):122-41. PubMed ID: 3023783
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacology of angiotensin converting enzyme inhibitors. A review.
    Nelson EB; Pool JL; Taylor AA
    Am J Med; 1986 Oct; 81(4C):13-8. PubMed ID: 3022580
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Angiotensin converting enzyme inhibitors and moderate hypertension.
    McAreavey D; Robertson JI
    Drugs; 1990 Sep; 40(3):326-45. PubMed ID: 2226219
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 36.